EA201892194A1 - Композиции комплекса трехвалентного железа с мальтолом для применения для лечения или предотвращения рака и опухолей - Google Patents

Композиции комплекса трехвалентного железа с мальтолом для применения для лечения или предотвращения рака и опухолей

Info

Publication number
EA201892194A1
EA201892194A1 EA201892194A EA201892194A EA201892194A1 EA 201892194 A1 EA201892194 A1 EA 201892194A1 EA 201892194 A EA201892194 A EA 201892194A EA 201892194 A EA201892194 A EA 201892194A EA 201892194 A1 EA201892194 A1 EA 201892194A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cancer
prevention
treatment
compositions
complex
Prior art date
Application number
EA201892194A
Other languages
English (en)
Inventor
Джонатан Джозеф Пауэлл
Дора И.А. Перейра
Original Assignee
Юнайтед Киндом Рисёрч Энд Инновейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юнайтед Киндом Рисёрч Энд Инновейшн filed Critical Юнайтед Киндом Рисёрч Энд Инновейшн
Publication of EA201892194A1 publication Critical patent/EA201892194A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Описано применение композиций комплекса трехвалентного железа с мальтолом для лечения или предотвращения рака и опухолей, в частности для лечения или предотвращения желудочно-кишечных раковых заболеваний или желудочно-кишечных опухолей, таких как рак толстого кишечника (толстой и прямой кишок), рак тонкого кишечника или рак верхних отделов желудочно-кишечного тракта.
EA201892194A 2016-03-31 2017-03-31 Композиции комплекса трехвалентного железа с мальтолом для применения для лечения или предотвращения рака и опухолей EA201892194A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201605474 2016-03-31
PCT/EP2017/057705 WO2017167972A1 (en) 2016-03-31 2017-03-31 Ferric maltol compositions for use in the treatment or prevention of cancer and tumours

Publications (1)

Publication Number Publication Date
EA201892194A1 true EA201892194A1 (ru) 2019-04-30

Family

ID=58461351

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201892194A EA201892194A1 (ru) 2016-03-31 2017-03-31 Композиции комплекса трехвалентного железа с мальтолом для применения для лечения или предотвращения рака и опухолей

Country Status (9)

Country Link
US (1) US11406664B2 (ru)
EP (1) EP3435999B1 (ru)
JP (1) JP6938534B2 (ru)
KR (1) KR102341615B1 (ru)
CN (1) CN109310667B (ru)
AU (1) AU2017242908B2 (ru)
CA (1) CA3019478C (ru)
EA (1) EA201892194A1 (ru)
WO (1) WO2017167972A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113975295B (zh) * 2021-11-15 2023-03-17 西北农林科技大学 麦芽酚铁过氧化物模拟酶在杀菌中的应用
WO2024030855A2 (en) * 2022-08-01 2024-02-08 Vitamax Patch Wholesaler Llc Systems and methods for transdermal patch delivery

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211500D0 (en) 2002-05-18 2002-06-26 Vitra Pharmaceuticals Ltd Method of forming iron hydroxypyrone compounds
GB0808835D0 (en) * 2008-05-15 2008-06-18 Vitra Pharmaceuticals Ltd Therapeutic compositions
US20120288531A1 (en) * 2011-01-14 2012-11-15 Shmuel Tuvia pharmaceutical compositions for delivery of ferric iron compounds, and methods of use thereof
GB201101370D0 (en) 2011-01-27 2011-03-09 Iron Therapeutics Holdings Ag Process
WO2014165607A2 (en) * 2013-04-02 2014-10-09 Stealth Peptides International, Inc. Aromatic-cationic peptide formulations, compositions and methods of use
EP3091974B1 (en) * 2014-01-06 2020-04-01 Shield TX (UK) Limited Dosage regimen of ferric trimaltol

Also Published As

Publication number Publication date
CN109310667B (zh) 2022-01-11
WO2017167972A1 (en) 2017-10-05
JP6938534B2 (ja) 2021-09-22
CA3019478A1 (en) 2017-10-05
US11406664B2 (en) 2022-08-09
EP3435999A1 (en) 2019-02-06
CN109310667A (zh) 2019-02-05
EP3435999B1 (en) 2021-04-28
AU2017242908B2 (en) 2022-11-17
JP2019513149A (ja) 2019-05-23
US20200306293A1 (en) 2020-10-01
KR20190026649A (ko) 2019-03-13
AU2017242908A1 (en) 2018-11-22
KR102341615B1 (ko) 2021-12-21
CA3019478C (en) 2024-02-13

Similar Documents

Publication Publication Date Title
SG11202106435QA (en) Treating gastric cancer using ttfields combined with xelox or folfox
MX2021003389A (es) Metodos para tratar el cancer.
CL2017000589A1 (es) Nuevos compuestos como inhibidores de reorganizado durante la transfección (ret)
MX2017015473A (es) Tratamiento contra el cancer por manipulacion de la microflora comensal.
MX2017004715A (es) Anticuerpos anti-ox40 humanizados y usos de los mismos.
EA201890272A1 (ru) Axl-специфические конъюгаты антитело-лекарственное средство для лечения рака
MX2020011796A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
MX2020011782A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
WO2016059602A3 (en) Combination therapy with anti-her3 antibodies to treat cancer
EA201692100A1 (ru) Новые антитела против rnf43 и способы их применения
MX2022008100A (es) Uso de compuestos de cloroquina y clemizol para el tratamiento de afecciones inflamatorias y cancerosas.
EA201790502A1 (ru) Ингибиторы гистоновых диметилаз
EA201791736A1 (ru) Комбинированная терапия для лечения рака
CY1119549T1 (el) Συνδυαστικη θεραπεια που περιλαμβανει αντισωματα κλωντινης 18.2 για τη θεραπεια του καρκινου
EP3693022A3 (en) Cox-2-targeting, platinum-containing conjugates and their use in the treatment of tumors and cancers
MX2019009356A (es) Sulfinilpiridinas y su uso en el tratamiento del cancer.
EA201891527A1 (ru) Композиции и способы обнаружения и лечения рака пищевода
MX2019008233A (es) Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral.
WO2014198919A3 (en) Tumor marker, monoclonal antibodies and methods of use thereof
EA201891528A1 (ru) Композиции и способы обнаружения и лечения рака желудка
EA201892194A1 (ru) Композиции комплекса трехвалентного железа с мальтолом для применения для лечения или предотвращения рака и опухолей
MX2017010341A (es) Terapia para cancer con un parvovirus combinado con bevacizumab.
EA201990370A1 (ru) Терапия рака, связанная с crebbp
EA201991166A1 (ru) Ректальный инсулин для лечения воспалительных заболеваний кишечника
MX2021005784A (es) Compuestos que inhiben de manera selectiva y efectiva la biquitinación mediada por hakai, como fármacos anti-cáncer.